Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBT for 17 consecutive years, with -$8.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 77.24% to -$8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$395.1 million through Dec 2025, down 220.18% year-over-year, with the annual reading at -$395.1 million for FY2025, 219.92% down from the prior year.
  • EBT for Q4 2025 was -$8.9 million at Myriad Genetics, up from -$26.2 million in the prior quarter.
  • The five-year high for EBT was $39.8 million in Q3 2021, with the low at -$330.6 million in Q2 2025.
  • Average EBT over 5 years is -$48.9 million, with a median of -$34.8 million recorded in 2023.
  • The sharpest move saw EBT surged 191.08% in 2021, then tumbled 788.71% in 2025.
  • Over 5 years, EBT stood at -$43.5 million in 2021, then dropped by 19.77% to -$52.1 million in 2022, then surged by 38.0% to -$32.3 million in 2023, then decreased by 21.05% to -$39.1 million in 2024, then surged by 77.24% to -$8.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$8.9 million, -$26.2 million, and -$330.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.